Mendeley出力
＜博士論文＞
肺癌切除患者におけるMTH1発現と腫瘍の悪性度、及び予後不良因子との関連
| 作成者 | |
|---|---|
| 論文調査委員 | |
| 本文言語 | |
| 学位授与年度 | |
| 学位授与大学 | |
| 学位 | |
| 学位種別 | |
| 出版タイプ | |
| アクセス権 | |
| JaLC DOI | |
| 関連DOI | |
| 概要 | OBJECTIVES:he oxidized purine nucleoside triphosphatase, mutT homolog 1 (MTH1), physiologically sanitizes 8-oxo-dGTP in the nucleotide pool. Previous studies indicated that MTH1 is associated with tum...or proliferation and invasion in non-small cell lung cancer (NSCLC) cell lines; however, the role of MTH1 in patients with NSCLC remains unclear. MATERIALS AND METHODS:Two patient cohorts that underwent surgery for NSCLC in our institution were investigated retrospectively. In one cohort consisting of 197 patients, the associations between MTH1 expression and clinicopathological factors or prognosis were analyzed. In another cohort consisting of 41 patients, the relationship between MTH1 expression in the tumors and serum oxidative stress levels (evaluated by the diacron-reactive oxygen metabolites [d-ROMs] test) or antioxidant capacity in the patients (evaluated by the biological antioxidant potential (BAP) test) was analyzed. A total of 238 patients were assessed for MTH1 protein levels using immunohistochemistry. RESULTS:Among the 197 patients in the former cohort, 111 (56.3%) exhibited high MTH1 expression, while 86 (43.7%) exhibited low MTH1 expression. Male sex, smoking habit of ≥20 pack-years, squamous cell carcinoma, pathological stage ≥ II, tumor diameter ≥30mm, lymph node metastases, pleural invasion, lymphatic permeation and vascular infiltration were significantly associated with high MTH1 expression (p<0.05). The high MTH1 expression group had a significantly worse prognosis than that of the low MTH1 expression group (5-year overall survival: 81.6% vs. 92.3%, p=0.0011; 5-year disease-free survival: 55.0% vs. 83.7%, p=0.0002). d-ROMs and BAP test values were significantly higher in the high than in the low MTH1 expression group (p<0.05). CONCLUSION:This study showed that MTH1 protein expression was closely related to factors associated with a high malignant potential and poor patient survival. MTH1 may be a novel therapeutic target for NSCLC.続きを見る |
本文ファイル
| ファイル | ファイルタイプ | サイズ | 閲覧回数 | 説明 |
|---|---|---|---|---|
med3063
|
586 KB | 703 | 本文 | |
|
med3063_abstract
|
116 KB | 205 | 要旨 | |
|
med3063_review
|
173 KB | 160 | 審査結果要旨 |
詳細
| レコードID | |
|---|---|
| 査読有無 | |
| 権利関係 | |
| 関連PubMed ID | |
| 報告番号 | |
| 学位記番号 | |
| 授与日(学位/助成/特許) | |
| 受理日 | |
| 部局 | |
| 登録日 | 2018.05.09 |
| 更新日 | 2020.01.31 |